SyncAV Post-Market Trial

NCT ID: NCT04100148

Last Updated: 2025-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

NA

Total Enrollment

1686 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-10-03

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The SyncAV Post-Market Trial is a prospective, randomized, multi-center trial performed to determine if cardiac resynchronization therapy (CRT) devices programmed with SyncAV ON improve long-term CRT response compared to devices programmed with conventional CRT through evaluation of changes in left ventricular (LV) reverse remodeling.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The SyncAV Post-Market Trial is designed as a prospective, randomized, multi-center trial. The trial will require physicians to implant an Abbott CRT device and Abbott Quadripolar LV lead with any available right atrial and right ventricular leads. Sites will randomize subjects in a 1:1 ratio within 2 - 6 weeks post successful CRT implant: Arm 1 - SyncAV CRT programmed ON; Arm 2 - programmed fixed atrioventricular (AV) delay.

For those subjects randomized to SyncAV programmed ON, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF), at biventricular (BiV) pacing nominal settings, with various SyncAV programmed offsets, and at LV first 30 ms, RV first 30 ms and LV-only pacing with optimal SyncAV offsets. The site will then program the subject's device using the SyncAV offset that provided the narrowest QRS duration.

For those subjects randomized to the fixed AV delay arm, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF) and at BiV pacing nominal settings. Sites will then program the subject's device using BiV pacing nominal settings.

Sites will collect data at baseline (before CRT implant), randomization, and at 3-month, 6-month, and 12-month visits. For subjects randomized to the SyncAV ON arm, sites will optimize the SyncAV feature again at 3 months and 6 months in the same manner as the randomization visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congestive Heart Failure

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

SyncAV feature CRT optimization CRT non-responders ECG optimization Cardiac remodeling CRT with SyncAV

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SyncAV Arm

Treatment Arm

Group Type EXPERIMENTAL

SyncAV programmed ON

Intervention Type DEVICE

For those subjects randomized to SyncAV programmed ON, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF), at BiV pacing nominal settings, with various SyncAV programmed offsets, and at LV first 30 ms, RV first 30 ms and LV-only pacing with optimal SyncAV offsets. The site will then program the subject's device using the SyncAV offset that provided the narrowest QRS duration.

Fixed AV Delay Arm

Control Arm

Group Type ACTIVE_COMPARATOR

Fixed AV delay

Intervention Type DEVICE

For those subjects randomized to the fixed AV delay arm, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF) and at BiV pacing nominal settings. Sites will then program the subject's device using BiV pacing nominal settings.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SyncAV programmed ON

For those subjects randomized to SyncAV programmed ON, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF), at BiV pacing nominal settings, with various SyncAV programmed offsets, and at LV first 30 ms, RV first 30 ms and LV-only pacing with optimal SyncAV offsets. The site will then program the subject's device using the SyncAV offset that provided the narrowest QRS duration.

Intervention Type DEVICE

Fixed AV delay

For those subjects randomized to the fixed AV delay arm, sites will measure QRS duration with the subject's intrinsic rhythm (pacing OFF) and at BiV pacing nominal settings. Sites will then program the subject's device using BiV pacing nominal settings.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Scheduled to receive a new CRT implant or an upgrade (Abbott CRT device and Abbott Quadripolar LV lead) from an existing implantable cardioverter defibrillator/pacemaker implant with no more than 10% RV pacing at the last device interrogation, no prior LV lead placement, AND meet the following additional criteria:

1. Mild to severe heart failure despite optimal medical therapy for at least 3 months prior to signing consent. Optimal medical therapy is defined as maximal tolerated dose of beta-blockers and a therapeutic dose of angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or aldosterone antagonist
2. LVEF ≤ 35% based on a prior standard of care echocardiogram
3. Left bundle branch block (LBBB) as documented on an ECG. Criteria for complete LBBB should include,

i. QRS duration ≥ 120 ms ii. QS or rS pattern in leads V1 iii. mid-QRS notching or slurring in leads I, aVL, V5, and V6 iv. Absence of Q-wave in leads V5 and V6 d. Intact AV conduction (PR interval ≤ 280 ms on surface ECG)
2. At least 18 years old, or of legal age and willing and capable to give informed consent specific to each country and national laws
3. Willing and able to comply with the prescribed follow-up tests and schedule of evaluations

Exclusion Criteria

1. Recent myocardial infarction or unstable angina within 40 days prior to signing consent
2. Recent cardiac revascularization (angioplasty, stent or bypass graft) in the 4 weeks prior to signing consent or planned within 3 months following consent
3. Cerebrovascular accident or transient ischemic attack in the 3 months prior to signing consent
4. Any other therapeutic cardiovascular procedure (transcatheter aortic valve replacement, MitraClip, cardiac surgery, left atrial appendage closure, patent foramen ovale closure, or any ablation procedures) in the 3 months prior to signing consent
5. Permanent or persistent AF at the time of signing consent
6. Paroxysmal AF with at least one cardioversion within 60 days prior to signing consent
7. Prior CRT device implant
8. Prior His Bundle pacing implant or plan to have His Bundle pacing implant
9. Pregnant or breastfeeding at the time of signing consent
10. Incapacitated or unable to read or write
11. Undergone cardiac transplantation or have a classification of Status 1 for cardiac transplantation or consideration for transplantation during the study follow-up period
12. Life expectancy \< 12 months due to any condition
13. Unavailable for at least 12 months of follow-up visits
14. Enrolled in or intend to participate in a clinical drug and/or device study during this clinical trial which could confound the results of this trial as determined by Abbott
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott Medical Devices

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Niraj Varma, MD

Role: PRINCIPAL_INVESTIGATOR

The Cleveland Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Heart Center Research, LLC.

Huntsville, Alabama, United States

Site Status

Arizona Cardiovascular Research Center

Phoenix, Arizona, United States

Site Status

HonorHealth

Scottsdale, Arizona, United States

Site Status

Comprehensive Cardiovascular

Bakersfield, California, United States

Site Status

Cardiovascular Consultants Heart Center

Fresno, California, United States

Site Status

USC University Hospital

Los Angeles, California, United States

Site Status

Colorado Heart & Vascular, P.C.

Lakewood, Colorado, United States

Site Status

Shands at the University of Florida

Gainesville, Florida, United States

Site Status

Heart Rhythm Solutions

Hollywood, Florida, United States

Site Status

Piedmont Heart Institute

Atlanta, Georgia, United States

Site Status

Emory University Hospital

Atlanta, Georgia, United States

Site Status

Iowa Heart Center

West Des Moines, Iowa, United States

Site Status

Baptist Health Lexington

Lexington, Kentucky, United States

Site Status

Sparrow Clinical Research Institute

Lansing, Michigan, United States

Site Status

Washington University School of Medicine

St Louis, Missouri, United States

Site Status

Catholic Medical Center

Manchester, New Hampshire, United States

Site Status

Deborah Heart & Lung Center

Browns Mills, New Jersey, United States

Site Status

Cardiovascular Associates of the Delaware Valley

Haddon Heights, New Jersey, United States

Site Status

Lourdes Cardiology Services

Voorhees Township, New Jersey, United States

Site Status

New York Presbyterian Brooklyn Methodist Hospital

Brooklyn, New York, United States

Site Status

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Site Status

The Toledo Hospital

Toledo, Ohio, United States

Site Status

Hightower Clinical

Oklahoma City, Oklahoma, United States

Site Status

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

Site Status

Medical University of South Carolina

Charleston, South Carolina, United States

Site Status

CHI St. Luke's Health Baylor College of Medicine Med. Ctr.

Houston, Texas, United States

Site Status

Memorial Katy Cardiology Associates

Houston, Texas, United States

Site Status

South Texas Cardiovascular Consultants

San Antonio, Texas, United States

Site Status

Heart Rhythm Associates

Shenandoah, Texas, United States

Site Status

Sentara Norfolk General Hospital

Norfolk, Virginia, United States

Site Status

Universitätsklinik Graz

Graz, Styria, Austria

Site Status

Hopital Erasme

Brussels, , Belgium

Site Status

Foothills Medical Centre

Calgary, Alberta, Canada

Site Status

St. Paul's Hospital

Vancouver, British Columbia, Canada

Site Status

Royal Jubilee Hospital

Victoria, British Columbia, Canada

Site Status

Hopital du Sacre-Coeur de Montreal

Montreal, Montreal, Canada

Site Status

HSC, Eastern Health

St. John's, Newfoundland and Labrador, Canada

Site Status

QE II Health Sciences

Halifax, Nova Scotia, Canada

Site Status

Kingston General Hospital

Kingston, Ontario, Canada

Site Status

St. Mary's General Hospital

Kitchener, Ontario, Canada

Site Status

Cardiac Arrhythmia Research Group Inc. (CARGI)

Scarborough Village, Ontario, Canada

Site Status

St. Michael's Hospital

Toronto, Ontario, Canada

Site Status

Institut de Cardiologie de Montreal (Montreal Heart Inst.)

Montreal, Quebec, Canada

Site Status

McGill University Health Centre General Hospital

Montreal, Quebec, Canada

Site Status

CHUS Fleurimont

Sherbrooke, Quebec, Canada

Site Status

Royal Alexandra Hospital

Edmonton, , Canada

Site Status

CHUM

Montreal, , Canada

Site Status

Institut de Cardiologie de Quebec (Hôpital Laval)

Québec, , Canada

Site Status

Tianjin Chest Hospital

Tianjin, Heping, China

Site Status

The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, Shaanxi, China

Site Status

Sir Run Run Shaw Hospital

Hangzhou, Zhejiang, China

Site Status

Helsinki University Central Hospital (HYKS)

Helsinki, , Finland

Site Status

CHU Rangueil Toulouse

Toulouse, Midi-Pyrenees, France

Site Status

CHRU Hopital de Pontchaillou

Rennes, , France

Site Status

St-Etienne CHU

Saint-Priest-en-Jarez, , France

Site Status

Hopital Henri Mondor

Créteil, Île-de-France Region, France

Site Status

CHR de La Reunion - Site du CHFG

Saint-Denis, Île-de-France Region, France

Site Status

Klinikum der Ruprecht-Karls-Universität Heidelberg

Heidelberg, Bad-wur, Germany

Site Status

Herzzentrum Dresden GmbH Universitätsklinik

Dresden, Saxony, Germany

Site Status

Kerckhoff-Klinik gGmbH

Bad Nauheim, , Germany

Site Status

The University of Hong Kong (Queen Mary Hospital)

Hong Kong, , Hong Kong

Site Status

Asian Institute of Gastroenterology (AIG) Hospital

Hyderabad, Andprad, India

Site Status

Care Institute of Medical Sciences

Ahmedabad, Gujarat, India

Site Status

Apollo Hospitals, Bangalore

Bangalore, Karnataka, India

Site Status

Narayana Institute of Cardiac Sciences, Bommasandra

Bangalore, Karnataka, India

Site Status

Medanta - The Medicity Hospital

Gūrgaon, , India

Site Status

Max Super Specialty Hospital

New Delhi, , India

Site Status

Mater Dei Hospital

Bari, Apulia, Italy

Site Status

Azienda Ospedaliera Di Venere

Carbonara, Apulia, Italy

Site Status

Azienda Ospedaliera Universitaria MaterDomini

Catanzaro, Calabria, Italy

Site Status

Azienda Ospedaliera S. G. Moscati

Avellino, , Italy

Site Status

Chiba University

Chiba, Chiba, Japan

Site Status

Hyogo College of Medicine

Nishinomiya, Hyōgo, Japan

Site Status

St. Marianna University School of Medicine Hospital

Kawasaki, Kanagawa, Japan

Site Status

Kitasato University Hospital

Sagamihara, Kanagwa, Japan

Site Status

Amsterdam Academic Medical Centre (AMC)

Amsterdam, Noord-h, Netherlands

Site Status

Scanmed SA

Krakow, Lesrpld, Poland

Site Status

Szpital Kliniczny Przemienienia Panskiego UM w Poznaniu

Poznan, , Poland

Site Status

Santa Maria Hospital

Lisbon, , Portugal

Site Status

Arrhythmia Group LLC

Ponce, , Puerto Rico

Site Status

Meshalkin National Medical Research Center

Novosibirsk, Siberia, Russia

Site Status

King Fahad Armed Forces Hospital

Jeddah, Mecca Region, Saudi Arabia

Site Status

King Faisal Specialist Hospital (KFSH)

Riyadh, Riyadh Region, Saudi Arabia

Site Status

King Fahad Medical City

Riyadh, , Saudi Arabia

Site Status

Clinical Center of Serbia - Pacemaker Center

Belgrade, , Serbia

Site Status

Sejong Hospital

Bucheon-si, Sudogwn, South Korea

Site Status

Keimyung University Dongsan Medical Center

Daegu, Sudogwn, South Korea

Site Status

Seoul National University Bundang Hospital

Seongnam, Sudogwn, South Korea

Site Status

Samsung Medical Center

Seoul, Sudogwon, South Korea

Site Status

Keimyung University Dongsan Medical Center

Daegu, , South Korea

Site Status

Asan Medical Centre

Seoul, , South Korea

Site Status

Severance Hospital, Yonsei University Health System

Seoul, , South Korea

Site Status

Hospital Universitario Infanta Cristina

Badajoz, , Spain

Site Status

Hospital Clínic de Barcelona

Barcelona, , Spain

Site Status

Fundación Jiménez Díaz

Madrid, , Spain

Site Status

Hospital Puerta de Hierro - Hospital Universitario

Madrid, , Spain

Site Status

HCU Virgen de la Victoria

Málaga, , Spain

Site Status

Hospital Universitario de Salamanca

Salamanca, , Spain

Site Status

Karolinska University Hospital, Solna

Stockholm, , Sweden

Site Status

Taichung Veterans General Hospital

Taichung, , Taiwan

Site Status

Phramongkutklao Hospital

Bangkok, Central Thailand, Thailand

Site Status

Southampton University Hospital

Southampton, Soeast, United Kingdom

Site Status

John Radcliffe Hospital

Oxford, South East England, United Kingdom

Site Status

The Royal Sussex County Hospital

Brighton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia Colombia Singapore Switzerland United Arab Emirates United States Austria Belgium Canada China Finland France Germany Hong Kong India Italy Japan Netherlands Poland Portugal Puerto Rico Russia Saudi Arabia Serbia South Korea Spain Sweden Taiwan Thailand United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ABT-CIP-10299

Identifier Type: -

Identifier Source: org_study_id